Mylan Metformina generics 500 mg

Mylan Metformina is a generic pharmaceutical product used primarily for the treatment of type 2 diabetes. Originally part of the portfolio of Mylan, a company founded in the United States, the brand underwent a significant corporate transformation in late 2020. Mylan merged with Pfizer's Upjohn division to form a new global healthcare entity named Viatris. This merger consolidated a vast array of generic and off-patent branded medicines under a single corporate umbrella.

While the brand's roots are American, the manufacturing of generic metformin occurs in a global network of facilities to meet worldwide demand, often involving sites in India, Europe, or North America depending on the specific batch and regional market. Currently, Viatris operates as a publicly traded global company headquartered in the United States, positioning itself as a leader in providing access to affordable, high-quality medicines for patients globally.